TICKERNERD
Menu
IFRXIFRXHealthcare · Biotechnology

IFRX Stock Forecast: InflaRx NV Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.53
−1.92% on the day

The 9 Wall Street analysts covering InflaRx NV hold a median 12-month price target of $7.78 — +408.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$229.9M
Ticker Nerd rank
7 / 100
Median analyst target
$7.78
Analysts covering
9
Revenue$0.0−100.0% y/y
Operating income−$7.0M
Net income−$10.6M
Free cash flow−$2.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.5%
1M
−29.5%
YTD
+51.5%
1Y
+4.1%
From 52W high
−44.2%
From 52W low
+85.5%
$0.83
$2.74
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IFRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores InflaRx NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
7 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
66
Momentum
65
Revisions
53
Volatility
18
Value
14
Issuance
13
Growth
8
Accruals
8
Quality
2

Size (66): Smaller than most of the companies we track.

Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IFRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IFRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26IFRXHigh $13.61Median $7.78Low $2.92

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $2.92Median $7.78High $13.61

The green dot is the last close — the median target sits +408.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Sept 2026NeedhamInitiatesBuy$8.00
7 Aug 2026Cantor FitzgeraldMaintainsOverweight$4.00 → $6.00
7 Aug 2026Cantor FitzgeraldMaintainsOverweight—
13 May 2026Raymond JamesUpgradeStrong Buy—
13 May 2026Raymond JamesUpgradeStrong Buy$7.00 → $9.00
11 May 2026Cantor FitzgeraldMaintainsOverweight$2.00 → $4.00
11 May 2026Cantor FitzgeraldMaintainsOverweight—
11 May 2026HC Wainwright & Co.MaintainsBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy$6.00 → $8.00
21 Apr 2026GuggenheimReiteratesBuy—
20 Mar 2026GuggenheimMaintainsBuy—
30 Dec 2025HC Wainwright & Co.ReiteratesBuy—
3 Dec 2025Leerink PartnersDowngradeMarket Perform—
10 Nov 2025GuggenheimMaintainsBuy—
2 Sept 2025HC Wainwright & Co.AssumesBuy$6.00
29 May 2025OppenheimerMaintainsOutperform—
8 May 2025OppenheimerInitiatesOutperform—
29 Apr 2025Cantor FitzgeraldInitiatesOverweight—
26 Mar 2025GuggenheimMaintainsBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IFRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IFRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, InflaRx NV returned +4.1% against +16.2% for the S&P 500, dividends included.

IFRX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26IFRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IFRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

InflaRx NV (IFRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 86% of US stocks

Price / sales
−22103.0×

Cheaper than 99% of US stocks

Price / book
1.4×

Cheaper than 59% of US stocks

EV / EBITDA
−2.1×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
352965.0%

Higher than 99% of US stocks

Net margin
−24677.9%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−38.5%

Higher than 25% of US stocks

Return on assets
−18.5%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

InflaRx NV (IFRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • InflaRx NV has a market value of $229.9M and an enterprise value of $84.6M.

  • Revenue in the twelve months to 30 June 2026: −$10K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$39.1M, a 387053.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$23.8M.

  • Shares outstanding: 147.4M.

  • Trailing P/E: −2.2×; forward P/E: −3.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • InflaRx NV employs 65 people — −$155.4 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

IFRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IFRXInflaRx NV$229.9M
7
MGNXMacroGenics, Inc.$225.6M
65
GLSIGreenwich LifeSciences, Inc.$222.2M
42
KROSKeros Therapeutics, Inc.$229.5M
71
SLGLSol-Gel Technologies Ltd.$229.9M
45
ALECAlector, Inc.$220.5M
50
EVMNEvommune, Inc.$230.9M
10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own InflaRx NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IFRX news & analysis

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

GlobeNewsWire · 2 Oct 2026positive

InflaRx announced it has been selected to present late-breaking pre-clinical data on its candidate izicopan at the American Society of Nephrology's Kidney Week 2026, to be held October 21-25 in Denver, Colorado.

Why it matters — A late-breaking poster selection at a major nephrology conference highlights continued scientific progress for izicopan, a key pipeline asset for InflaRx.

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

GlobeNewsWire · 1 Oct 2026positive

InflaRx N.V. announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical Development, effective October 1, 2026. The company develops anti-inflammatory therapeutics targeting the complement system.

Why it matters — The appointment of a new senior clinical development leader could strengthen InflaRx's clinical-stage capabilities as it advances its complement-targeting pipeline.

InflaRx to Host Virtual Capital Markets Day

GlobeNewsWire · 21 Sept 2026neutral

InflaRx has announced it will host a virtual Capital Markets Day on November 3, 2026 at 8:00 AM EST. Featured speakers at the event will include Peter A. Merkel, MD, MPH and Prof.

Why it matters — IFRX watchers may be interested as the Capital Markets Day presents an opportunity for the company to share information with investors through its featured speakers.

InflaRx Announces Participation in September Investor Conferences

GlobeNewsWire · 20 Aug 2026neutral

InflaRx N.V. announced it will participate in two investor conferences in September 2026, as detailed in a company release on Aug. 20, 2026. The announcement provides the scheduled dates for these investor engagements.

Why it matters — Investor conference participation offers InflaRx watchers opportunities to hear updates on the company's complement-system therapeutics program.

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

GlobeNewsWire · 6 Aug 2026positive

InflaRx announced its second quarter 2026 financial results and provided a business update. The company reported progress on izicopan for ANCA-associated vasculitis and select renal diseases, initiated a feasibility assessment for a broader European AAV strategy, released new preclinical data, and plans a PK bridging study in China late this year, with cash of €158.4 million expected to fund operations through 2029. A Virtual Capital Markets Day is planned for October 8, 2026.

Why it matters — The update details izicopan's clinical advancement, upcoming proof-of-concept milestones, and a cash runway through 2029, giving InflaRx investors clarity on near-term catalysts and financial staying power.

FAQ

Frequently asked questions about IFRX stock

What is the IFRX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering InflaRx NV have a median 12-month price target of $7.78, with estimates ranging from $2.92 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IFRX stock a buy right now?

Of the 9 analysts covering InflaRx NV, 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InflaRx NV 7 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IFRX?

As at 8 Oct 2026, InflaRx NV ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (66 of 100).

Will IFRX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +408.3% from the last close, and Ticker Nerd's factor model ranks InflaRx NV 7 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IFRX stock forecast for 2030?

No analyst covering InflaRx NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IFRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.92 to $14 over the next 12 months.

How has IFRX stock performed over the past year?

InflaRx NV returned +4.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InflaRx NV do?

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways.

What is the latest news on IFRX?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026". InflaRx announced it has been selected to present late-breaking pre-clinical data on its candidate izicopan at the American Society of Nephrology's Kidney Week 2026, to be held October 21-25 in Denver, Colorado.

Company

About InflaRx NV.

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio centers on proprietary antibody and small-molecule programs designed to address autoimmune and other inflammatory diseases through precise modulation of immune signaling. Its current pipeline includes vilobelimab, an intravenously administered anti-C5a antibody, and an oral C5aR inhibitor in development for inflammatory indications. InflaRx serves the biotechnology and healthcare sectors, with research and operational activities in Germany and the United States. The company’s work is centered on advancing novel treatments for severe inflammatory conditions where targeted complement inhibition may play an important therapeutic role.

CEO Prof. Niels C. Riedemann M.D., Ph.D. · 65 employees · Germany · https://www.inflarx.de